Literature DB >> 18484792

Restless legs syndrome: pathophysiology, diagnosis and treatment.

Pankaj Satija1, William G Ondo.   

Abstract

Restless legs syndrome (RLS) is clinically defined by the presence of (i) an urge to move the legs with or without an actual paraesthesia; (ii) a worsening of symptoms with inactivity; (iii) improvement with activity; and (iv) a worsening of symptoms in the evening and at night. Patients may use a variety of semantic phrases to describe their symptoms but all must have an urge to move. Most people with RLS also have periodic limb movements during sleep, although this is not part of the clinical diagnostic criteria. RLS is very common. About 10% of all Caucasian populations have RLS, although it may be mild in the majority of cases. Women generally outnumber men by about 2:1. As a general rule, RLS severity worsens through the first seven to eight decades of life, but may actually lessen in old age. The aetiology of RLS is only partly understood. There is a strong genetic component, and several genetic linkages and three causative genes have been identified worldwide. Several medical conditions, including renal failure, systemic iron deficiency and pregnancy, and possibly neuropathy, essential tremor and some genetic ataxias, are also associated with high rates of RLS. In all cases to date, the actual CNS pathology of RLS demonstrates reduced iron stores, in a pattern that suggests that the homeostatic control of iron is altered, not just that there is not enough iron entering the brain. The relationship between reduced CNS iron levels and the clinical phenotype or treatment response to dopaminergics is not known but generates promising speculation. Treatment of RLS is usually rewarding. Most patients respond robustly to dopamine receptor agonists. Over time, response may lessen, or the patients may develop 'augmentation', whereby they have a worsening of symptoms, usually in the form of an earlier onset. Other treatment options include gabapentin, or similar antiepileptic drugs, and opioids. High-dose intravenous iron is a promising but still experimental approach.

Entities:  

Mesh:

Year:  2008        PMID: 18484792     DOI: 10.2165/00023210-200822060-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  298 in total

1.  Daytime sleepiness, agonist therapy, and driving in Parkinson disease.

Authors:  Cynthia L Comella
Journal:  JAMA       Date:  2002 Jan 23-30       Impact factor: 56.272

2.  Mirtazapine may have the propensity for developing a restless legs syndrome? A case report.

Authors:  Won-Myong Bahk; Chi-Un Pae; Jeong-Ho Chae; Tae-Youn Jun; Kwang-Soo Kim
Journal:  Psychiatry Clin Neurosci       Date:  2002-04       Impact factor: 5.188

3.  Gabapentin improved sensory and motor symptoms in the restless legs syndrome.

Authors:  Alberto Albanese; Graziella Filippini
Journal:  ACP J Club       Date:  2003 Jul-Aug

4.  Circadian rhythm of restless legs syndrome: relationship with biological markers.

Authors:  Martin Michaud; Marie Dumont; Brahim Selmaoui; Jean Paquet; Maria Livia Fantini; Jacques Montplaisir
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

5.  Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron.

Authors:  K A Lee; M E Zaffke; K Baratte-Beebe
Journal:  J Womens Health Gend Based Med       Date:  2001-05

6.  Treatment of the restless legs syndrome with clonazepam.

Authors:  W B Matthews
Journal:  Br Med J       Date:  1979-03-17

7.  Pramipexole in the treatment of restless legs syndrome: a follow-up study.

Authors:  J Montplaisir; R Denesle; D Petit
Journal:  Eur J Neurol       Date:  2000-05       Impact factor: 6.089

8.  Amantadine is beneficial in restless legs syndrome.

Authors:  V G Evidente; C H Adler; J N Caviness; J G Hentz; K Gwinn-Hardy
Journal:  Mov Disord       Date:  2000-03       Impact factor: 10.338

9.  Restless legs syndrome in end-stage renal disease.

Authors:  J W Winkelman; G M Chertow; J M Lazarus
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

10.  The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study.

Authors:  Sarah von Spiczak; Alan L Whone; Alexander Hammers; Marie-Claude Asselin; Federico Turkheimer; Tobias Tings; Svenja Happe; Walter Paulus; Claudia Trenkwalder; David J Brooks
Journal:  Brain       Date:  2005-02-23       Impact factor: 13.501

View more
  18 in total

Review 1.  Essential tremor--a neurodegenerative disorder associated with cognitive defects?

Authors:  Félix Bermejo-Pareja
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

2.  Prevalence of restless legs syndrome in patients with irritable bowel syndrome.

Authors:  P Patrick Basu; N James Shah; Nithya Krishnaswamy; Tommy Pacana
Journal:  World J Gastroenterol       Date:  2011-10-21       Impact factor: 5.742

3.  Restless Eating, Restless Legs, and Sleep Related Eating Disorder.

Authors:  Michael J Howell
Journal:  Curr Obes Rep       Date:  2014-03

4.  The higher prevalence of non-right handers among patients with restless leg syndrome.

Authors:  Shadi Ghourchian; Parviz Bahrami
Journal:  Neurol Sci       Date:  2014-07-02       Impact factor: 3.307

5.  Restless legs syndrome is frequent in narcolepsy with cataplexy patients.

Authors:  Giuseppe Plazzi; Raffaele Ferri; Elena Antelmi; Sophie Bayard; Christian Franceschini; Filomena I I Cosentino; Beatriz Abril; Karen Spruyt; Federica Provini; Pasquale Montagna; Yves Dauvilliers
Journal:  Sleep       Date:  2010-05       Impact factor: 5.849

6.  In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.

Authors:  Yumi Oboshi; Yasuomi Ouchi; Shunsuke Yagi; Satoshi Kono; Noriyoshi Nakai; Etsuji Yoshikawa; Masami Futatsubashi; Tatsuhiro Terada; Kang Kim; Kiyoshi Harada
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-11       Impact factor: 6.200

Review 7.  Parasomnias: an updated review.

Authors:  Michael J Howell
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

8.  Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

Authors:  R Savica; B R Grossardt; J M Carlin; M Icen; J H Bower; J E Ahlskog; D M Maraganore; D P Steensma; W A Rocca
Journal:  Neurology       Date:  2009-10-27       Impact factor: 9.910

9.  Celiac disease is associated with restless legs syndrome.

Authors:  Leonard B Weinstock; Arthur S Walters; Gerard E Mullin; Stephen P Duntley
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

10.  Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.

Authors:  Stefan D Anker; Josep Comin Colet; Gerasimos Filippatos; Ronnie Willenheimer; Kenneth Dickstein; Helmut Drexler; Thomas F Lüscher; Claudio Mori; Barbara von Eisenhart Rothe; Stuart Pocock; Philip A Poole-Wilson; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2009-11       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.